Key result
US cardiovascular disease costs exceed $500 billion annually and may top $1 trillion by 2035.
The economic burden of cardiovascular disease in the US is massive and projected to exceed $1 trillion by 2035, highlighting an urgent need for prevention, value-based care, and equitable access.
Cardiovascular disease (CVD) is the leading cause of death in the United States and a major driver of healthcare spending.Combined direct costs such as hospitalizations, procedures, and medications with indirect costs from lost productivity and caregiving exceed $500 billion each year and are expected to surpass $1 trillion by 2035.Wide cost variation across health systems underscores inefficiencies and inequities.Women, older adults, and racial and ethnic minorities bear a disproportionate financial burden, which worsens existing health disparities.In conclusion, addressing this crisis requires a comprehensive approach that emphasizes prevention, equitable access, value-based care, and reduction of waste through streamlined administration and fair pricing.Sustainable strategies are essential to improve outcomes, contain costs, and narrow disparities as the prevalence of CVD continues to rise.
No takes yet. Share an insight, caveat, or question.
Nikoo et al. (2026) conducted a review in Cardiovascular disease. Cardiovascular disease imposes a massive economic burden in the United States, with annual costs exceeding $500 billion and projected to surpass $1 trillion by 2035.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: